Goldman Sachs Reaffirms Neutral Rating on AMAG Pharmaceuticals (AMAG)
Other equities research analysts have also recently issued reports about the stock. Analysts at Ladenburg Thalmann downgraded shares of AMAG Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note to investors on Thursday. They now have a $19.00 price target on the stock. Separately, analysts at Robert W. Baird downgraded shares of AMAG Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday. They now have a $17.00 price target on the stock, down previously from $21.00. Finally, analysts at Jefferies Group (NYSE: JEF) reiterated an “underperform” rating on shares of AMAG Pharmaceuticals in a research note to investors on Tuesday, March 6th.
Shares of AMAG Pharmaceuticals traded down 0.74% during mid-day trading on Friday, hitting $13.152. AMAG Pharmaceuticals has a 52 week low of $12.65 and a 52 week high of $19.62. The company’s market cap is $280.9 million.
AMAG Pharmaceuticals last announced its earnings results on Tuesday, May 1st. The company reported ($0.58) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.63) by $0.05. The company’s quarterly revenue was up 15.7% on a year-over-year basis. On average, analysts predict that AMAG Pharmaceuticals will post $0.31 earnings per share next quarter.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which utilizes the technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and imaging agents to aid in the diagnosis of cancer and cardiovascular disease.